Coronary heart disease is one of the leading diseases that threaten the health of urban and rural residents in China. Recent studies have shown that chronic inflammation is the core pathogenic mechanism of the induction and development of atherosclerosis, and various pathways of inflammatory response have become targets for the treatment of coronary heart disease. However, no specific target anti-inflammatory drugs have been recommended for secondary prevention of coronary heart disease. The CANOTOS study, published at the European Society of Cardiology Congress 2017 (ESC 2017), confirmed that canakinumab significantly reduces cardiovascular risk in the target population through anti-inflammatory action. This landmark study reveals that anti-inflammatory therapy is a new chapter in the treatment of coronary heart disease after the age of traditional lipid-lowering and antithrombotic therapy. In recent years, rapid progress has been made in the research of targeted anti-inflammatory drugs for various types of coronary heart disease. The current progress in the research of targeted anti-inflammatory therapy for coronary heart disease is reviewed.